{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:07:54Z","timestamp":1778476074504,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Training Program of Innovation and Entrepreneurship","award":["202411065010"],"award-info":[{"award-number":["202411065010"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81803895"],"award-info":[{"award-number":["No.81803895"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MH266"],"award-info":[{"award-number":["ZR2024MH266"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04897-7","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:12:09Z","timestamp":1778472729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic anti-tumor activity of andrographolide and gemcitabine in intrahepatic cholangiocarcinoma through inhibition of RRM2 and the JAK\/STAT3 pathway"],"prefix":"10.1007","volume":"96","author":[{"given":"Qinghang","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruolan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"2","key":"4897_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/hep.0000000000000437","volume":"79","author":"L Shu","year":"2023","unstructured":"Shu L, Li X, Liu Z et al (2023) Bile exosomal MiR-182\/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation. Hepatology 79(2):307\u2013322. https:\/\/doi.org\/10.1097\/hep.0000000000000437","journal-title":"Hepatology"},{"key":"4897_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2025.100569","volume":"35","author":"O Sahat","year":"2025","unstructured":"Sahat O, Bilheem S, Lim A et al (2025) Updated cholangiocarcinoma incidence trends and projections in Thailand by region based on data from four population-based cancer registries. Lancet Reg Health Southeast Asia 35:100569. https:\/\/doi.org\/10.1016\/j.lansea.2025.100569","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"4897_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16199","author":"S Lei","year":"2025","unstructured":"Lei S, Huang G, Li X et al (2025) Global burden, trends, and inequalities of gallbladder and biliary tract cancer, 1990\u20132021: a decomposition and age\u2013period\u2013cohort analysis. Liver Int. https:\/\/doi.org\/10.1111\/liv.16199","journal-title":"Liver Int"},{"issue":"3","key":"4897_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1073274817729245","volume":"24","author":"NN Massarweh","year":"2017","unstructured":"Massarweh NN, El-Serag HB (2017) Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 24(3):107327481772924. https:\/\/doi.org\/10.1177\/1073274817729245","journal-title":"Cancer Control"},{"issue":"4","key":"4897_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jhepr.2019.06.003","volume":"1","author":"E Loeuillard","year":"2019","unstructured":"Loeuillard E, Conboy CB, Gores GJ et al (2019) Immunobiology of cholangiocarcinoma. JHEP Rep 1(4):297\u2013311. https:\/\/doi.org\/10.1016\/j.jhepr.2019.06.003","journal-title":"JHEP Rep"},{"issue":"3","key":"4897_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101290","volume":"7","author":"Z Li","year":"2025","unstructured":"Li Z, Aliseda D, Jones O et al (2025) Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data. JHEP Rep 7(3):101290. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101290","journal-title":"JHEP Rep"},{"issue":"3","key":"4897_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/jco.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle M, Lowery M, Shroff RT et al (2018) Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 36(3):276\u2013282. https:\/\/doi.org\/10.1200\/jco.2017.75.5009","journal-title":"J Clin Oncol"},{"issue":"2","key":"4897_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2022","unstructured":"Moris D, Palta M, Kim C et al (2022) Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and\u00a0future\u00a0therapeutic landscape for clinicians. CA Cancer J Clin 73(2):198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"4897_CR9","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/nejmoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T et al (2023) Nivolumab plus Gemcitabine\u2013Cisplatin in advanced urothelial carcinoma. N Engl J Med 389(19):1778\u20131789. https:\/\/doi.org\/10.1056\/nejmoa2309863","journal-title":"N Engl J Med"},{"issue":"3","key":"4897_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10637-012-9863-1","volume":"31","author":"A Mortazavi","year":"2012","unstructured":"Mortazavi A, Ling Y, Martin LK et al (2012) A Phase I study of prolonged infusion of Triapine in combination with fixed dose rate Gemcitabine in patients with advanced solid tumors. Invest New Drugs 31(3):685\u2013695. https:\/\/doi.org\/10.1007\/s10637-012-9863-1","journal-title":"Invest New Drugs"},{"issue":"5 Suppl 10","key":"4897_CR11","first-page":"3","volume":"23","author":"W Plunkett","year":"1996","unstructured":"Plunkett W, Huang P, Searcy CE et al (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23(5 Suppl 10):3\u201315","journal-title":"Semin Oncol"},{"key":"4897_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200015","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S et al (2022) Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. https:\/\/doi.org\/10.1056\/evidoa2200015","journal-title":"NEJM Evid"},{"issue":"5","key":"4897_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/1078-0432.ccr-22-2036","volume":"29","author":"TH Patel","year":"2022","unstructured":"Patel TH, Marcus L, Horiba MN et al (2022) FDA approval summary: Pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement. Clin Cancer Res 29(5):838\u2013842. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-2036","journal-title":"Clin Cancer Res"},{"key":"4897_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jare.2021.12.005","volume":"40","author":"C Glorieux","year":"2022","unstructured":"Glorieux C, Xia X, You X et al (2022) Cisplatin and Gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-Ras-driven cancer. J Adv Res 40:109\u2013124. https:\/\/doi.org\/10.1016\/j.jare.2021.12.005","journal-title":"J Adv Res"},{"issue":"6","key":"4897_CR15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/s2468-1253(22)00043-7","volume":"7","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Lee K-H, Lee D-W et al (2022) Gemcitabine and Cisplatin plus Durvalumab with or without Tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, Phase 2 study. Lancet Gastroenterol Hepatol 7(6):522\u2013532. https:\/\/doi.org\/10.1016\/s2468-1253(22)00043-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10391","key":"4897_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/s0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with Gemcitabine and Cisplatin compared with Gemcitabine and Cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853\u20131865. https:\/\/doi.org\/10.1016\/s0140-6736(23)00727-4","journal-title":"Lancet"},{"issue":"sup1","key":"4897_CR17","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1080\/10408398.2018.1501657","volume":"59","author":"Y Dai","year":"2018","unstructured":"Dai Y, Chen S-R, Chai L et al (2018) Overview of pharmacological activities of Andrographis paniculata and its major compound Andrographolide. Crit Rev Food Sci Nutr 59(sup1):S17\u2013S29. https:\/\/doi.org\/10.1080\/10408398.2018.1501657","journal-title":"Crit Rev Food Sci Nutr"},{"key":"4897_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2195-8","author":"J Gao","year":"2019","unstructured":"Gao J, Peng S, Shan X et al (2019) Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-019-2195-8","journal-title":"Cell Death Dis"},{"key":"4897_CR19","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.2147\/jir.s422342","volume":"16","author":"L Yu","year":"2023","unstructured":"Yu L, Liu Y, Cao C et al (2023) Andrographolide attenuates inflammation due to intra-abdominal sepsis by enhancing bacterial clearance in mice. J Inflamm Res 16:4413\u20134423. https:\/\/doi.org\/10.2147\/jir.s422342","journal-title":"J Inflamm Res"},{"key":"4897_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18319-0","author":"RP Yadav","year":"2022","unstructured":"Yadav RP, Sadhukhan S, Saha ML et al (2022) Exploring the mechanism of Andrographolide in the treatment of gastric cancer through network pharmacology and molecular docking. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-022-18319-0","journal-title":"Sci Rep"},{"issue":"1","key":"4897_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.toxlet.2013.06.241","volume":"222","author":"G-Q Bao","year":"2013","unstructured":"Bao G-Q, Shen B-Y, Pan C-P et al (2013) Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of Gemcitabine in pancreatic cancer. Toxicol Lett 222(1):23\u201335. https:\/\/doi.org\/10.1016\/j.toxlet.2013.06.241","journal-title":"Toxicol Lett"},{"issue":"1","key":"4897_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010119","volume":"11","author":"K Okuno","year":"2023","unstructured":"Okuno K, Xu C, Pascual-Sabater S et al (2023) Andrographis reverses Gemcitabine resistance through regulation of ERBB3 and calcium signaling pathway in pancreatic ductal adenocarcinoma. Biomedicines 11(1):119. https:\/\/doi.org\/10.3390\/biomedicines11010119","journal-title":"Biomedicines"},{"issue":"1","key":"4897_CR23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/ptr.7324","volume":"36","author":"B Zeng","year":"2021","unstructured":"Zeng B, Wei A, Zhou Q et al (2021) Andrographolide: a review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches. Phytother Res 36(1):336\u2013364. https:\/\/doi.org\/10.1002\/ptr.7324","journal-title":"Phytother Res"},{"issue":"6","key":"4897_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biom12060815","volume":"12","author":"SE Huff","year":"2022","unstructured":"Huff SE, Winter JM, Dealwis CG (2022) Inhibitors of the cancer target ribonucleotide reductase, past and present. Biomolecules 12(6):815. https:\/\/doi.org\/10.3390\/biom12060815","journal-title":"Biomolecules"},{"issue":"6464","key":"4897_CR25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1126\/science.aau6391","volume":"366","author":"Y Lu","year":"2019","unstructured":"Lu Y, Zheng Y, Coyaud \u00c9 et al (2019) Palmitoylation of NOD1 and NOD2 is required for bacterial sensing. Science 366(6464):460\u2013467. https:\/\/doi.org\/10.1126\/science.aau6391","journal-title":"Science"},{"key":"4897_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202100881","author":"W Xiong","year":"2021","unstructured":"Xiong W, Zhang B, Yu H et al (2021) RRM2 regulates sensitivity to Sunitinib and PD\u20101 blockade in renal cancer by stabilizing ANXA1 and activating the AKT pathway. Adv Sci. https:\/\/doi.org\/10.1002\/advs.202100881","journal-title":"Adv Sci"},{"key":"4897_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01689-8","author":"Y Yang","year":"2020","unstructured":"Yang Y, Lin J, Guo S et al (2020) RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer. Cancer Cell Int. https:\/\/doi.org\/10.1186\/s12935-020-01689-8","journal-title":"Cancer Cell Int"},{"issue":"1","key":"4897_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.gendis.2022.11.022","volume":"11","author":"Z Zuo","year":"2024","unstructured":"Zuo Z, Zhou Z, Chang Y et al (2024) Ribonucleotide reductase M2 (RRM2): regulation, function and targeting strategy in human cancer. Genes Dis 11(1):218\u2013233. https:\/\/doi.org\/10.1016\/j.gendis.2022.11.022","journal-title":"Genes Dis"},{"key":"4897_CR29","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.14432","volume":"10","author":"Y Li","year":"2022","unstructured":"Li Y, Fu W, Geng Z et al (2022) A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors. PeerJ 10:e14432. https:\/\/doi.org\/10.7717\/peerj.14432","journal-title":"PeerJ"},{"issue":"1","key":"4897_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","volume":"136","author":"JJ Farrell","year":"2009","unstructured":"Farrell JJ, Elsaleh H, Garcia M et al (2009) Human equilibrative nucleoside transporter 1 levels predict response to Gemcitabine in patients with pancreatic cancer. Gastroenterology 136(1):187\u2013195. https:\/\/doi.org\/10.1053\/j.gastro.2008.09.067","journal-title":"Gastroenterology"},{"issue":"21","key":"4897_CR31","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1158\/1078-0432.ccr-14-0542","volume":"20","author":"M Kerr","year":"2014","unstructured":"Kerr M, Scott HE, Groselj B et al (2014) Deoxycytidine kinase expression underpins response to Gemcitabine in bladder cancer. Clin Cancer Res 20(21):5435\u20135445. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-0542","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4897_CR32","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.ccr-16-0626","volume":"23","author":"H Mameri","year":"2017","unstructured":"Mameri H, Bi\u00e8che I, Meseure D et al (2017) Cytidine deaminase deficiency reveals new therapeutic opportunities against cancer. Clin Cancer Res 23(8):2116\u20132126. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-0626","journal-title":"Clin Cancer Res"},{"issue":"16","key":"4897_CR33","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/onc.2014.155","volume":"34","author":"Y Aye","year":"2014","unstructured":"Aye Y, Li M, Long MJC et al (2014) Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene 34(16):2011\u20132021. https:\/\/doi.org\/10.1038\/onc.2014.155","journal-title":"Oncogene"},{"key":"4897_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66945-7","author":"P Thongpon","year":"2024","unstructured":"Thongpon P, Intuyod K, Chomwong S et al (2024) Curcumin synergistically enhances the efficacy of Gemcitabine against Gemcitabine-resistant cholangiocarcinoma via the targeting LAT2\/glutamine pathway. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-024-66945-7","journal-title":"Sci Rep"},{"key":"4897_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-025-01180-y","author":"J Ren","year":"2025","unstructured":"Ren J, Su T, Ding J et al (2025) Chlorophyllin exerts synergistic anti-tumor effect with Gemcitabine in pancreatic cancer by inducing cuproptosis. Mol Med. https:\/\/doi.org\/10.1186\/s10020-025-01180-y","journal-title":"Mol Med"},{"issue":"11","key":"4897_CR36","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1080\/15384101.2023.2207247","volume":"22","author":"X Ma","year":"2023","unstructured":"Ma X, Fu T, Ke Z-Y et al (2023) MiR-17- 5p\/RRM2 regulated Gemcitabine resistance in lung cancer A549 cells. Cell Cycle 22(11):1367\u20131379. https:\/\/doi.org\/10.1080\/15384101.2023.2207247","journal-title":"Cell Cycle"},{"key":"4897_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-017-0579-0","author":"G Xia","year":"2017","unstructured":"Xia G, Wang H, Song Z et al (2017) Gambogic acid sensitizes Gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-017-0579-0","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"4897_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051083","volume":"13","author":"C Boden","year":"2025","unstructured":"Boden C, Esser LK, Dold L et al (2025) The IL-6\/JAK\/STAT3 axis in cholangiocarcinoma and primary sclerosing cholangitis: unlocking therapeutic strategies through patient-derived organoids. Biomedicines 13(5):1083. https:\/\/doi.org\/10.3390\/biomedicines13051083","journal-title":"Biomedicines"},{"key":"4897_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0926-9","author":"Y Peng","year":"2018","unstructured":"Peng Y, Wang Y, Tang N et al (2018) Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of P300 signaling and VEGF pathway. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-018-0926-9","journal-title":"J Exp Clin Cancer Res"},{"key":"4897_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00827","author":"P Pearngam","year":"2019","unstructured":"Pearngam P, Kumkate S, Okada S et al (2019) Andrographolide inhibits cholangiocarcinoma cell migration by down-regulation of Claudin-1 via the p-38 signaling pathway. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2019.00827","journal-title":"Front Pharmacol"},{"key":"4897_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01691-2","author":"H Hong","year":"2022","unstructured":"Hong H, Cao W, Wang Q et al (2022) Synergistic antitumor effect of Andrographolide and Cisplatin through ROS-mediated ER stress and STAT3 inhibition in colon cancer. Med Oncol. https:\/\/doi.org\/10.1007\/s12032-022-01691-2","journal-title":"Med Oncol"},{"key":"4897_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01621-y","author":"Y Cao","year":"2020","unstructured":"Cao Y, Wang J, Tian H et al (2020) Mitochondrial ROS accumulation inhibiting JAK2\/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-020-01621-y","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"4897_CR43","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/1878-0261.12928","volume":"15","author":"T Lahiri","year":"2021","unstructured":"Lahiri T, Brambilla L, Andrade J et al (2021) Mitochondrial STAT3 regulates antioxidant gene expression through Complex I\u2010derived NAD in triple negative breast cancer. Mol Oncol 15(5):1432\u20131449. https:\/\/doi.org\/10.1002\/1878-0261.12928","journal-title":"Mol Oncol"},{"issue":"2","key":"4897_CR44","doi-asserted-by":"publisher","first-page":"12800","DOI":"10.1080\/21655979.2021.2001241","volume":"12","author":"M Yang","year":"2021","unstructured":"Yang M, Yao P, Lang X et al (2021) Ribonucleotide reductase subunit M2 promotes proliferation and epithelial\u2013mesenchymal transition via the JAK2\/STAT3 signaling pathway in retinoblastoma. Bioengineered 12(2):12800\u201312811. https:\/\/doi.org\/10.1080\/21655979.2021.2001241","journal-title":"Bioengineered"},{"issue":"1","key":"4897_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010217","volume":"9","author":"W Jin","year":"2020","unstructured":"Jin W (2020) Role of JAK\/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial\u2013mesenchymal transition. Cells 9(1):217. https:\/\/doi.org\/10.3390\/cells9010217","journal-title":"Cells"},{"key":"4897_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03174-w","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Xue S, Wei D et al (2024) Membrane RRM2-positive cells represent a malignant population with cancer stem cell features in Intrahepatic Cholangiocarcinoma. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-024-03174-w","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"4897_CR47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0944-7113(00)80054-9","volume":"7","author":"A Panossian","year":"2000","unstructured":"Panossian A, Hovhannisyan A, Mamikonyan G et al (2000) Pharmacokinetic and oral bioavailability of andrographolide from Andrographis paniculata fixed combination Kan Jang in rats and human. Phytomedicine 7(5):351\u2013364. https:\/\/doi.org\/10.1016\/s0944-7113(00)80054-9","journal-title":"Phytomedicine"},{"key":"4897_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.952660","author":"P Songvut","year":"2022","unstructured":"Songvut P, Suriyo T, Panomvana D et al (2022) A comprehensive review on disposition kinetics and dosage of oral administration of Andrographis paniculata, an alternative herbal medicine, in co-treatment of coronavirus disease. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.952660","journal-title":"Front Pharmacol"},{"issue":"9","key":"4897_CR49","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.drudis.2019.05.017","volume":"24","author":"HL Soo","year":"2019","unstructured":"Soo HL, Quah SY, Sulaiman I et al (2019) Advances and challenges in developing andrographolide and its analogues as cancer therapeutic agents. Drug Discov Today 24(9):1890\u20131898. https:\/\/doi.org\/10.1016\/j.drudis.2019.05.017","journal-title":"Drug Discov Today"},{"key":"4897_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26278-8","author":"S Reabroi","year":"2018","unstructured":"Reabroi S, Saeeng R, Boonmuen N et al (2018) The anti-cancer activity of an Andrographolide analogue functions through a GSK-3\u03b2-independent Wnt\/\u03b2-Catenin signaling pathway in Colorectal Cancer cells. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-018-26278-8","journal-title":"Sci Rep"},{"issue":"12","key":"4897_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29122884","volume":"29","author":"G Messire","year":"2024","unstructured":"Messire G, Rollin P, Gillaizeau I et al (2024) Synthetic modifications of andrographolide targeting new potential anticancer drug candidates: a comprehensive overview. Molecules 29(12):2884. https:\/\/doi.org\/10.3390\/molecules29122884","journal-title":"Molecules"},{"key":"4897_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.639409","author":"BA Oseni","year":"2021","unstructured":"Oseni BA, Azubuike CP, Okubanjo OO et al (2021) Encapsulation of Andrographolide in poly(lactide-co-glycolide) nanoparticles: formulation optimization and in vitro efficacy studies. Front Bioeng Biotechnol. https:\/\/doi.org\/10.3389\/fbioe.2021.639409","journal-title":"Front Bioeng Biotechnol"},{"key":"4897_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2023.2174209","author":"T Neamatallah","year":"2023","unstructured":"Neamatallah T, Malebari AM, Alamoudi AJ et al (2023) Andrographolide nanophytosomes exhibit enhanced cellular delivery and pro-apoptotic activities in HepG2 Liver Cancer cells. Drug Deliv. https:\/\/doi.org\/10.1080\/10717544.2023.2174209","journal-title":"Drug Deliv"},{"issue":"1","key":"4897_CR54","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/13880209.2024.2311201","volume":"62","author":"P Songvut","year":"2024","unstructured":"Songvut P, Boonyarattanasoonthorn T, Nuengchamnong N et al (2024) Enhancing oral bioavailability of andrographolide using solubilizing agents and bioenhancer: comparative pharmacokinetics of Andrographis paniculata formulations in beagle dogs. Pharm Biol 62(1):183\u2013194. https:\/\/doi.org\/10.1080\/13880209.2024.2311201","journal-title":"Pharm Biol"},{"issue":"4","key":"4897_CR55","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1021\/acs.molpharmaceut.7b01164","volume":"15","author":"X Kang","year":"2018","unstructured":"Kang X, Zheng Z, Liu Z et al (2018) Liposomal codelivery of Doxorubicin and Andrographolide inhibits breast cancer growth and metastasis. Mol Pharm 15(4):1618\u20131626. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b01164","journal-title":"Mol Pharm"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04897-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04897-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04897-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:12:11Z","timestamp":1778472731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04897-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4897"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04897-7","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}